脊髄損傷後の炎症性微小環境の時空間的無秩序

Spinal cord injury is a severe neurological condition with far-reaching consequences for both individuals and society. Its progression involves a complex interplay between the initial mechanical insult and inflammation-driven secondary injury. This review interprets recent studies on the spatiotemporal map of the inflammatory microenvironment in spinal cord injury and other neurological disorders, focusing on the latest mechanistic research and treatment options. The postinjury inflammatory microenvironment comprises diverse immune and glial cell populations whose phenotypes and functions change over time. The current consensus suggests that inflammation has a paradoxical nature: while it can limit lesion spread in the acute stage, chronic or dysregulated responses contribute to further neural damage through pathways such as excitotoxicity, oxidative stress, and glial scar formation. Methods such as spatiotemporal transcriptomic analyses and organoid-based models have improved our ability to resolve cell-cell interactions and discover new molecular targets. Numerous therapies targeting this microenvironment have been developed. Stem cell-based approaches, especially human umbilical cord mesenchymal stem cells, show promise in promoting tissue regeneration and immune regulation in experimental and early clinical studies. Bioengineering methods such as using biomaterial scaffolds and controlled drug release are being investigated to improve drug delivery and the injury microenvironment. Pharmacological efforts to modify cytokine networks, oxidative pathways, or immune checkpoints have achieved some success, hampered by patient heterogeneity and injury patterns. Persistent challenges include determining the context-specific mechanisms, identifying the best treatment windows, and combining a few methods for the best effect. In summary, detailed understanding of the spatiotemporal dynamics of post-spinal cord injury inflammation is essential for designing targeted interventions. Future directions include integrating multiomics datasets, identifying predictive biomarkers for patient stratification, and developing adaptive treatment protocols that fine-tune rather than suppress immune responses to promote neural repair and functional recovery.